Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
About this study
Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years. Findings of liver MRIs as reported by radiology PI will be shared with their local MDT who make decisions as appropriate, including the management of any identified liver metastases, according to local protocol.
- Condition
- Colorectal Neoplasms, Neoplasm Metastases, Hepatic Neoplasms
- Tested
- Diffusion Weighted MRI scan
- Sponsor
- Imperial College London
Who can join
- Age
- 16 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 16 years
- Study condition: Colorectal Neoplasms, Neoplasm Metastases, Hepatic Neoplasms
- Have a high risk primary colorectal malignancy
- Have a negative CT or includes no confirmatory evidence of liver metastases
- Is able to undergo treatment if liver metastasis is found
- Have provided written informed consent to participate in the study
- Be aged 16 years or over
Exclusion 5
- Have had a previous colorectal malignancy
- Have metastatic disease
- Have a synchronous second malignancy
- Are contraindicated for MRI
- Has a T3b or below low rectal tumour without EMVI or N1c
Where
13 sites, 13 recruiting
Royal Bolton Hospital
Bolton, Greater Manchester, United Kingdom
Broomfield Hospital
Chelmsford, Essex, United Kingdom
Medway Maritime Hospital
Gillingham, Kent, United Kingdom
Royal Liverpool Hospital
Liverpool, Merseyside, United Kingdom
Macclesfield District General Hospital
Macclesfield, Cheshire, United Kingdom
Royal Gwent Hospital
Newport, Wales, United Kingdom
and 7 more sites on ClinicalTrials.gov
Contact
-
Caroline Martin
+44 (0) 7749 655 817 c.martin1@imperial.ac.uk
-
Syvella Ellis
+44 (0) 7732 315 234 giclinicaltrials@imperial.ac.uk
Potential match only. Final eligibility is determined by the study team.